AGN - Allergan plc

NYSE - NYSE Delayed price. Currency in USD
159.11
-0.14 (-0.09%)
At close: 4:00PM EDT

159.35 +0.24 (0.15%)
After hours: 7:17PM EDT

Stock chart is not supported by your current browser
Previous close159.25
Open160.00
Bid159.35 x 800
Ask159.33 x 800
Day's range159.04 - 161.19
52-week range114.27 - 197.00
Volume2,656,930
Avg. volume4,911,473
Market cap52.193B
Beta (3Y monthly)1.95
PE ratio (TTM)N/A
EPS (TTM)-25.50
Earnings date28 Oct. 2019 - 1 Nov. 2019
Forward dividend & yield2.96 (1.87%)
Ex-dividend date2019-08-12
1y target est181.38
Trade prices are not sourced from all markets
  • Here's Why Allergan is Outperforming Its Industry Of Late
    Zacks13 hours ago

    Here's Why Allergan is Outperforming Its Industry Of Late

    Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.

  • Financial Times7 days ago

    Correction: Allergan sale

    Allergan chief executive Brent Saunders disclosed the role of JPMorgan and Wachtell, Lipton, Rosen & Katz asadvisers to the company on its planned sale to AbbVie, not AbbVie chief executive Richard Gonzalez ...

  • Financial Times7 days ago

    Elliott bags Goldman’s Barg

    Top advisory shops, including the likes of Goldman Sachs and Morgan Stanley, have long shunned activists for fear of alienating their corporate clients. As a result, shareholder activism has become a lucrative business for banks hoping to cosy up to corporates in search of future business and hefty fees.

  • Bloomberg8 days ago

    Argentina Apoplexy, IPOs and Other Things to Watch on 13F Day

    (Bloomberg) -- As hedge fund holdings data pour in, investors will be keeping an eye on which managers may be exposed to the market apoplexy unfolding in Argentina.Managers including Autonomy Capital’s Robert Gibbins and Pointstate Capital’s Zach Schreiber started the year with bets on Argentine companies that trade in the U.S. After hedge funds finish reporting their end-of-June U.S. equity holdings Wednesday, investors will have an idea whether managers were adding to, or shedding, their positions in the nation during the months prior to the presidential primary elections held Sunday.President Mauricio Macri’s stunningly poor showing sent Argentina’s stocks, bonds and currency into a tailspin Monday as investors grappled with the idea that the market-friendly candidate will probably lose his re-election bid in October. They’re worried that opposition candidate Alberto Fernandez and his running mate, former president Cristina Fernandez de Kirchner, will bring back the protectionist policies that marked her administration.In an interview with Bloomberg in April, Gibbins, who manages about $5.5 billion, said he expected voters to ultimately elect a market-friendly candidate in October, even if it isn’t Macri.“Faced with the choice between going back to what they know to have failed, which was Cristina Kirchner, in kind of a profound de-institutionalization, I think that Argentines are going to choose to carry forward with the path -- whether it’s with Mauricio Macri, or with somebody else” from his party, Gibbins said.As of the end of March, Gibbins’s biggest publicly traded U.S. equity positions were in Argentine stocks, including mall operator IRSA Inversiones y Representaciones SA and banks Grupo Financiero Galicia SA and Banco Macro SA.Emerging markets, in general, have sold off as the rout in Argentina and escalating protests in Hong Kong spook investors already on edge over the trade war. As 13F filings come in, investors will also look to see who was exposed to the developing world, as well as these other themes:The so-called FAANG group of major technology and internet stocks. Google parent Alphabet Inc. suffered a big one-day drop in late April on the back of a disappointing earnings report, while Netflix Inc. in July reported disappointing subscriber numbers that sent shares falling.The underwhelming IPOs of the second quarter, including Uber Technologies Inc., and the eye-popping ones, like Beyond Meat Inc., Chewy Inc., Crowdstrike Holdings Inc. and Revolve Group Inc.Mergers and acquisitions, particularly AbbVie Inc.’s mega-deal to buy Botox maker Allergan Plc for $63 billion.Money managers who oversee more than $100 million in equities in the U.S. must file a Form 13F within 45 days of each quarter’s end to list those stocks as well as options and convertible bonds. The filings don’t show non-U.S. securities, holdings that aren’t publicly traded, or cash.To contact the reporters on this story: Katia Porzecanski in New York at kporzecansk1@bloomberg.net;Nishant Kumar in London at nkumar173@bloomberg.netTo contact the editors responsible for this story: Alan Mirabella at amirabella@bloomberg.net, Josh Friedman, Dan ReichlFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Implied Volatility Surging for Allergan (AGN) Stock Options
    Zacks8 days ago

    Implied Volatility Surging for Allergan (AGN) Stock Options

    Investors need to pay close attention to Allergan (AGN) stock based on the movements in the options market lately.

  • Here's Why Amgen Stock is Outperforming Its Industry Of Late
    Zacks8 days ago

    Here's Why Amgen Stock is Outperforming Its Industry Of Late

    Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

  • Can Value Investors Consider Allergan (AGN) a Worthy Pick?
    Zacks8 days ago

    Can Value Investors Consider Allergan (AGN) a Worthy Pick?

    Allergan (AGN) stock may be a good choice for value-oriented investors right now from multiple angles.

  • Financial Times8 days ago

    JPMorgan Chase set to scoop record fee for Allergan sale

    JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie. the $120m paid to Morgan Stanley for advising US agribusiness Monsanto on its $66bn sale to Germany’s Bayer in 2016, according to data from Dealogic. The details of the fee arrangement were disclosed by Allergan this week as it prepares for a shareholder vote on its sale to Chicago-based AbbVie.

  • Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
    Zacks12 days ago

    Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients

    Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.

  • Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down
    Zacks13 days ago

    Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down

    Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.

  • Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
    Zacks14 days ago

    Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO

    In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.

  • Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie
    Motley Fool15 days ago

    Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie

    The drugmaker's Q2 revenue and earnings beats enable it to raise full-year guidance.

  • Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
    Zacks15 days ago

    Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

    Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.

  • Company News For Aug 6, 2019
    Zacks15 days ago

    Company News For Aug 6, 2019

    Companies in the news are: AGN, ENR, EPC and MNK

  • Allergan (AGN) Surpasses Q2 Earnings and Revenue Estimates
    Zacks15 days ago

    Allergan (AGN) Surpasses Q2 Earnings and Revenue Estimates

    Allergan (AGN) delivered earnings and revenue surprises of 0.92% and 3.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Can Allergan (AGN) Keep the Earnings Surprise Streak Alive?
    Zacks16 days ago

    Can Allergan (AGN) Keep the Earnings Surprise Streak Alive?

    Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Is a Beat in Store for Melinta (MLNT) This Earnings Season?
    Zacks16 days ago

    Is a Beat in Store for Melinta (MLNT) This Earnings Season?

    Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.

  • Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?
    Zacks16 days ago

    Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?

    Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q2.

  • Allergan (AGN) Gains As Market Dips: What You Should Know
    Zacks19 days ago

    Allergan (AGN) Gains As Market Dips: What You Should Know

    Allergan (AGN) closed at $161.02 in the latest trading session, marking a +0.07% move from the prior day.

  • Proteostasis (PTI) to Post Q2 Earnings: What's in Store?
    Zacks20 days ago

    Proteostasis (PTI) to Post Q2 Earnings: What's in Store?

    Investors will focus on the cystic fibrosis studies, when Proteostasis (PTI) reports second-quarter 2019 earnings.

  • Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
    Zacks21 days ago

    Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

    Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

  • Should You Buy Allergan (AGN) Ahead of Earnings?
    Zacks21 days ago

    Should You Buy Allergan (AGN) Ahead of Earnings?

    Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Guardant Health (GH) to Report Q2 Earnings: What's in Store?
    Zacks23 days ago

    Guardant Health (GH) to Report Q2 Earnings: What's in Store?

    Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.

  • AbbVie Inc (ABBV) Q2 2019 Earnings Call Transcript
    Motley Fool26 days ago

    AbbVie Inc (ABBV) Q2 2019 Earnings Call Transcript

    ABBV earnings call for the period ending June 30, 2019.

  • What's in the Cards for Amarin (AMRN) This Earnings Season?
    Zacks26 days ago

    What's in the Cards for Amarin (AMRN) This Earnings Season?

    Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.